Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort

Authors:

Abstract
Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates are likely to suffer from a degree of uncontrolled confounding. To obtain causal estimates, we examined the role of pubertal development in prostate cancer using genetic polymorphisms associated with Tanner stage in adolescent boys in a Mendelian randomization (MR) approach. We derived a weighted genetic risk score for pubertal development, combining 13 SNPs associated with male Tanner stage. A higher score indicated a later puberty onset. We examined the association of this score with prostate cancer risk, stage and grade in the UK-based ProtecT case-control study (n = 2,927), and used the PRACTICAL consortium (n = 43,737) as a replication sample. In ProtecT, the puberty genetic score was inversely associated with prostate cancer grade (odds ratio (OR) of high- vs. low-grade cancer, per tertile of the score: 0.76; 95 % CI, 0.64–0.89). In an instrumental variable estimation of the causal OR, later physical development in adolescence (equivalent to a difference of one Tanner stage between pubertal boys of the same age) was associated with a 77 % (95 % CI, 43–91 %) reduced odds of high Gleason prostate cancer. In PRACTICAL, the puberty genetic score was associated with prostate cancer stage (OR of advanced vs. localized cancer, per tertile: 0.95; 95 % CI, 0.91–1.00) and prostate cancer-specific mortality (hazard ratio amongst cases, per tertile: 0.94; 95 % CI, 0.90–0.98), but not with disease grade. Older age at sexual maturation is causally linked to a reduced risk of later prostate cancer, especially aggressive disease.
Funding Information
  • World Cancer Research Fund (2011/419)
  • Cancer Research UK (C18281/A19169)
  • Medical Research Council (G0600705; MC_UU_12013/19)
  • Health Technology Assessment Programme (HTA 96/20/99; ISRCTN20141297)
  • Seventh Framework Programme (223175/HEALTH-F2-2009-223175)
  • Cancer Research UK (C1287/A10118; C1287/A10710; C12292/A11174; C1281/A12014; C5047/A8384; C5047/A15007; C5047/A10692; C8197/A16565)
  • National Institutes of Health (CA128978)
  • U.S. Department of War (W81XWH-10-1-0341)
  • Canadian Institutes of Health Research
  • Susan G. Komen for the Cure
  • Breast Cancer Research Foundation
  • Ovarian Cancer Research Fund
  • National Institute for Health Research
  • Post-Cancer GWAS initiative (1U19 CA148537; 1U19 CA148065; 1U19 CA148112)
  • The University of Bristol

This publication has 38 references indexed in Scilit: